Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterised by progressive cognitive decline and memory loss caused by both genetic and environmental factors. Synapse dysfunction and loss are strongly related to cognitive decline in AD. This study integrates genomic, transcriptomic, proteomic and immunohistological (multi-omics) data and longitudinal cognitive data across several AD cohorts to elucidate the molecular drivers associated with astrocytes and microglia involved in these processes. Our findings demonstrate that activation of microglia and astrocytes occurs in specific cell subsets that are enriched in AD risk genes. Transcriptomic evidence for early microglial activation precedes immunohistological expression of severe neuropathology. Proteomic markers of astrocytic response appear to be most strongly associated with accelerated cognitive decline. However, we also found that brains from donors with a history of more rapid cognitive decline showed evidence for reduced SNAP25-VAMP interactions indicative of synaptic dysfunction, exhibited higher neurotoxic astrocyte reactivity, and were associated with the expression of neuronal markers of injury. Related molecular signatures in cerebrospinal fluid and plasma may provide biomarkers to identify patients at higher risk for rapid cognitive decline. Together, our results connect glial activation to synaptic dysfunction and cognitive decline in AD and highlight roles for microglial activation in the genesis of AD and later astrocyte activation as a potential determinant of clinical symptom progression.
Competing Interest Statement
This study also was partly funded by Biogen IDEC. PMM has received consultancy fees from Sudo Biosciences, Ipsen Biopharm Ltd., Rejuveron Therapeutics and Biogen. He has received honoraria or speakers' fees from Novartis and Biogen and research or educational funds from BMS, Biogen, Novartis and GlaxoSmithKline.
Funding Statement
PMM acknowledges generous personal support from the Edmond J Safra Foundation and Lily Safra and an NIHR Senior Investigator Award. JSJ was supported by funding from Alzheimer's Society (grant number 599 (AS-DRL-22-008)). This work was supported by the UK Dementia Research Institute, which receives funding from UK DRI Ltd., funded by the UK Medical Research Council, Alzheimer's Society, and Alzheimer's Research UK. The study is from the UK Dementia Institute Multi-omics Atlas Project for Alzheimer's Disease (MAP-AD; map-ad.org). This study was partially supported by an investigator-initiated grant from Biogen IDEC to PMM and JSJ.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Internal cohort: This study was carried out in accordance with the Regional Ethics Committee and Imperial College Use of Human Tissue guidelines and according to the Human Tissue Act. Ethics committee of London Neurodegeneration [King's College London] gave ethical approval for this work. Ethics committee of Newcastle Brain Tissue Resource gave ethical approval for this work. Ethics committee of Queen's Square Brain Bank [University College London] gave ethical approval for this work. Ethics committee of Manchester Brain Bank gave ethical approval for this work. Ethics committee of Oxford Brain Bank gave ethical approval for this work. Ethics committee of South West Dementia Brain Bank [University of Bristol] gave ethical approval for this work. Ethics committee of Parkinson's UK [Imperial College London] Brain Bank gave ethical approval for this work. ROSMAP external cohort: Institutional Review Board (IRB) of Rush University Medical Center gave ethical approval for this work. MSBB external cohort: Mount Sinai Hospital Research Ethics Board (REB) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# Joint senior authors
Data Availability
Internal cohort UK DRI Multi-'omics Atlas Project This study's metadata and patient IDs can be found in the following Synapse repository: syn61606248. The BrainBankNetworkID in the sample sheet must be cross-referenced with the omics datasets to ensure the inclusion of the same donors. Proteomics: syn53424292 Transcriptomics: syn52943644 Histopathology: syn52658344 Single nuclei transcriptomics: syn53165790 Seurat objects of filtered microglia, astrocyte, and neuronal populations are available upon request. External cohorts Selected participants' IDs and related derived features (modules, cluster groups, PRS scores, etc.) used in the current study can be found in the study Synapse repository syn61606248 ROSMAP Transcriptomics and TMT proteomics data: Publicly available at Synapse under IDs syn4164376 and syn21971722, respectively. Whole genome sequencing: syn11707419 SNARE Synaptic Proteomics: Data can be requested from RADC Data Requests. MSBB Transcriptomics and TMT proteomics data: Publicly available at Synapse under IDs syn16796121 and syn24995077, respectively.
